Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Hutson TE, et al. Among authors: pittman kb. J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2. J Clin Oncol. 2014. PMID: 24297950 Free PMC article. Clinical Trial.
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. Motzer RJ, et al. J Clin Oncol. 2014 Sep 1;32(25):2765-72. doi: 10.1200/JCO.2013.54.6911. Epub 2014 Jul 21. J Clin Oncol. 2014. PMID: 25049330 Free PMC article. Clinical Trial.
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Knox JJ, et al. Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075. Ann Oncol. 2017. PMID: 28327953 Free PMC article. Clinical Trial.
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA. Ramalingam SS, et al. Among authors: pittman kb. J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5. J Clin Oncol. 2015. PMID: 25559798 Free PMC article. Clinical Trial.
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Knox JJ, et al. Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807. Ann Oncol. 2018. PMID: 29390043 Free PMC article. No abstract available.
Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer.
Takhar H, Singhal N, Mislang A, Kumar R, Kim L, Selva-Nayagam S, Pittman K, Karapetis C, Borg M, Olver IN, Brown MP. Takhar H, et al. Asia Pac J Clin Oncol. 2018 Feb;14(1):91-100. doi: 10.1111/ajco.12749. Epub 2017 Aug 25. Asia Pac J Clin Oncol. 2018. PMID: 28840978 Clinical Trial.
A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer.
Sukumaran S, Pittman KB, Patterson WK, Dickson J, Yeend S, Townsend A, Broadbridge V, Price TJ. Sukumaran S, et al. Among authors: pittman kb. Ann Oncol. 2010 May;21(5):1089-93. doi: 10.1093/annonc/mdp420. Epub 2009 Oct 21. Ann Oncol. 2010. PMID: 19846468 Free article. Clinical Trial.
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.
Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ; Adelaide Cancer Trials and Education Collaborative (ACTEC). Pittman KB, et al. Br J Cancer. 2006 Nov 20;95(10):1309-13. doi: 10.1038/sj.bjc.6603440. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088914 Free PMC article. Clinical Trial.
Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R. Wilcken N, et al. Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:1-14. doi: 10.1111/ajco.12206. Asia Pac J Clin Oncol. 2014. PMID: 24797445 Review.
60 results